Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 423-630-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The work described was performed in compliance with UK GLP standards (Schedule 1, Good Laboratory Practice Regulations 1997 (SI 1997/654)). These Regulations are in accordance with GLP standards published as OECD Principles on Good Laboratory Practice (revised 1997, ENV/MC/CHEM(98)17); and are in accordance with, and implement, the requirements of Directives 87/18/EEC and 88/320/EEC.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
- Report date:
- 1999
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
Test material
- Reference substance name:
- -
- EC Number:
- 423-630-1
- EC Name:
- -
- Cas Number:
- 62435-71-6
- Molecular formula:
- C7H14O2
- IUPAC Name:
- 2-(ethoxymethyl)oxolane
- Details on test material:
- Description, Identification and storage conditions
-Sponser's Identification: Ethyl Tetrahydrofurfuryl Ether
-Date Recieved: 18 November 1998
Data relating to the identity, purity and stability of the test material are responsibilty of the Sponsor.
-Description: Colourless Liquid
-Storage Conditions: Room Temperature in the dark under nitrogen
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Doses:
- Using all available information, 2000 mg/kg bodyweight was selected as the starting dose.
A group of three fasted females was treated with the starting dose of 2000 mg/kg. This was followed by a group of three fasted males at the same
dose level. - No. of animals per sex per dose:
- 3 females per starting dose of 2000 mg/kg
3 males per starting dose of 2000 mg/kg - Details on study design:
- The information available suggested a starting dose of 2000 mg/kg.
All animals were dosed once only by gavage, using a metal cannula attached to a graduate syringe. The volume administered to each animal was calculated according to the fasted bodyweight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each sex to confirm the survival of the previously dosed animals.
Animals were observed for deaths or overt signs of toxicity 1/2, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days.
Individual bodyweights were recorded prior to dosing and seven and fourteen days aftyer treatment.
At the end of the observtion period the animals were killed by cervical dislocation. All animals were subjected to gross pathological examination. This consisted of an external examination and opening of the abdominal and thoracic cavities for examination of major organs. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths
- Clinical signs:
- Common signs of systemic toxicity noted in males and females were prostration, loss of righting reflex, decreased respiratory rate, laboured respiration, coma, prosis and hunched posture. Dehydration and pilo-erection were also commonly noted in males with lethargy and ataxia also commonly noted in females. Incidents of increased salivation and emaciation were noted in males and incidents of dehydration and pilo-erection in females. Isolated incidents of lethargy were noted in males and isolated incidents of splayed gait and red/brown staining around eyes noted in females.
Females recovered three or four days after dosing and males recovered six days after dosing. - Body weight:
- All animals showed expected gains in bodyweight over the study period.
- Other findings:
- Necropsy: No abnormalties were noted at necrospy.
Any other information on results incl. tables
MORTALITY DATA
Dose Level mg/kg | Sex | Number of Animals Treated | Deaths During Day of Dosing (Hour) | Deaths During Period After Dosing (Days) | Deaths | |||||||||||
1/2 | 1 | 2 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 -14 | |||||
2000 | Male | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/3 | |
Female | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0/3 |
INDIVIDUAL BODYWEIGHTS AND WEEKLY BODYWEIGHT CHANGES: FEMALE
Dose Level mg/kg | Animal Number and Sex | Bodyweight (g) at Day | Bodyweight Gain (g) During Week | |||
0 | 7 | 14 | 1 | 2 | ||
2000 | 1 - 0 Female | 223 | 281 | 297 | 58 | 16 |
1 - 1 Female | 243 | 250 | 263 | 7 | 13 | |
1 - 2 Female | 238 | 271 | 282 | 33 | 11 |
INDIVIDUAL BODYWEIGHTS AND WEEKLY BODYWEIGHT CHANGES: MALE
Dose Level mg/kg | Animal Number and Sex | Bodyweight (g) at Day | Bodyweight Gain (g) During Week | |||
0 | 7 | 14 | 1 | 2 | ||
2000 | 2 - 0 Male | 216 | 254 | 323 | 38 | 69 |
2 - 1 Male | 219 | 271 | 342 | 52 | 71 | |
2 - 2 Male | 232 | 233 | 309 | 1 | 76 |
INDIVIDUAL CLINICAL OBSERVATIONS: FEMALE
Dose Level mg/kg | Animal Number and Sex | Effects Noted After Dosing (Hours) | Effects Noted During Period After Dosing (Days) | ||||||||||||||||
2000 | 1/2 | 1 | 2 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
1 - 0 Female | RrRdRl | RrRdRl | CoRd RlPt | CoRd RlPt | HPRd RdRl DhWs | HPRd RIDh | HP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
1 - 1 Female | PrRdRl | RrRdRl | CoRdRlPt | CoRdRlPt | HLARdRISe | H | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
1 - 2 Female | PrRdRl | RrRdRl | CoRdRlPt | CoRdRlPt | HLARdRI | H | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INDIVIDUAL CLINICAL OBSERVATIONS: MALE
Dose Level mg/kg | Animal Number and Sex | Effects Noted After Dosing (Hours) | Effects Noted During Period After Dosing (Days) | ||||||||||||||||
2000 | 1/2 | 1 | 2 | 4 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | |
2 - 0 Male | PrRdRl | RrRdRl | RrRdRl | CoRd RlPt | HLPRd RIDh | H | H | H | H | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
2 - 1 Male | HLARd RI | RrRdRl | RrRdRl | CoRdRlPt | HPDhRdRI | H | H | H | H | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
2 - 2 Male | HLASRdRI | PrSRdRI | RrRdRl | CoRdRlPt | HPRdRI | HPEm | HEm | H | H | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INDIVIDUAL NECROPSY FINDINGS: FEMALE
Dose Level mg/kg | Animal Number and Sex | Macroscopic Observations |
1 - 0 Female | No abnormalities detected | |
1 - 1 Female | No abnormalities detected | |
1 - 2 Female | No abnormalities detected |
INDIVIDUAL NECROPSY FINDINGS: MALE
Dose Level mg/kg | Animal Number and Sex | Macroscopic Observations |
2 - 0 Female | No abnormalities detected | |
2 - 1 Female | No abnormalities detected | |
2 - 2 Female | No abnormalities detected |
A= Ataxia
Co = Coma
Dh = Dehydration
Em = Emaciation
H = Hunched Posture
L = Lethargy
P = Pilo-erection
Pr = Prostration
Pt = Ptosis
Rd = Decreased respiratory rate
Rl = Laboured respiration
Rr = Loss of righting reflex
Ws = splayed gait
Se = red/brown staining around eyes
S= increased salivation
O = no signs of systemic toxicity
Applicant's summary and conclusion
- Conclusions:
- The acute oral LD50 of the test material, ETHYL TETRAHYDROFURFURYL, in the SPrague-Dawley CD strain rat was estimated to be greater than 2000 mg/kg.
No mortalities were noted at 2000 mg/kg bodyweight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1